The multicentre, open-label study is designed to assess safety and tolerability of SOR-C13, in addition to pharmacokinetics, biomarkers and initial evidence for efficacy.
Soricimed Biopharma chairman and chief scientific officer Jack Stewart said unlike chemotherapy, the company’s cancer treatment is highly targeted – affecting only cancer cells.
"Healthy cells are not affected. It’s also a biologic, meaning it’s derived from a naturally occurring peptide that when broken down produces amino acids that can be reused by the body," Stewart added.
"As a result, and this is key, there have been virtually no side effects demonstrated in our pre-clinical studies."
The company expects to carry out Phase I trials till February 2013 and to release interim results later in 2012. Based on successful results, further clinical trials will follow.